We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
"One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis.
- Authors
Ramatla, Tsepo; Mafokwane, Tshepo; Lekota, Kgaugelo; Monyama, Maropeng; Khasapane, George; Serage, Naledi; Nkhebenyane, Jane; Bezuidenhout, Carlos; Thekisoe, Oriel
- Abstract
Background: The Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) bacterial isolates that produce extended-spectrum β-lactamases (ESBLs) contribute to global life-threatening infections. This study conducted a systematic review and meta-analysis on the global prevalence of ESBLs in co-existing E. coli and K. pneumoniae isolated from humans, animals and the environment. Methods: The systematic review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) [ID no: CRD42023394360]. This study was carried out following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. One hundred and twenty-six eligible studies published on co-existing antibiotic resistance in E. coli and K. pneumoniae between 1990 and 2022 were included. Results: The pooled prevalence of ESBL-producing E. coli and K. pneumoniae was 33.0% and 32.7% for humans, 33.5% and 19.4% for animals, 56.9% and 24.2% for environment, 26.8% and 6.7% for animals/environment, respectively. Furthermore, the three types of resistance genes that encode ESBLs, namely blaSHVblaCTX−M,blaOXA, and blaTEM, were all detected in humans, animals and the environment. Conclusions: The concept of "One-Health" surveillance is critical to tracking the source of antimicrobial resistance and preventing its spread. The emerging state and national surveillance systems should include bacteria containing ESBLs. A well-planned, -implemented, and -researched alternative treatment for antimicrobial drug resistance needs to be formulated.
- Subjects
KLEBSIELLA pneumoniae; ESCHERICHIA coli; DRUG resistance in microorganisms; DRUG resistance in bacteria; DRUG resistance; ANTI-infective agents
- Publication
Annals of Clinical Microbiology & Antimicrobials, 2023, Vol 22, Issue 1, p1
- ISSN
1476-0711
- Publication type
Article
- DOI
10.1186/s12941-023-00638-3